Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Targeted therapy for psoriatic arthritis

Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. Novel therapies that target other cytokines have now been tested, with encouraging results.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Gladman, D. D. Psoriatic arthritis. Dermatol. Ther. 22, 40–55 (2009).

    Article  Google Scholar 

  2. 2

    Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).

    CAS  Article  Google Scholar 

  3. 3

    Soriano, E. R. & McHugh, N. J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33, 1422–1430 (2006).

    PubMed  Google Scholar 

  4. 4

    Ribbens, C. et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur. Cytokine Netw. 11, 669–676 (2000).

    CAS  PubMed  Google Scholar 

  5. 5

    Hueber, A. J. & McInnes, I. B. Immune regulation in psoriasis and psoriatic arthritis—recent developments. Immunol. Lett. 114, 59–65 (2007).

    CAS  Article  Google Scholar 

  6. 6

    Ravindran, V., Scott, D. L. & Choy, E. H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum. Dis. 67, 855–859 (2008).

    CAS  Article  Google Scholar 

  7. 7

    Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41, 199–204 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Hüffmeier, U. et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355–358 (2009).

    Article  Google Scholar 

  9. 9

    Rahman, P. et al. Association of interleukin-23R variants with psoriatic arthritis. J. Rheumatol. 36, 137–140 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Dafna D. Gladman.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gladman, D. Targeted therapy for psoriatic arthritis. Nat Rev Rheumatol 5, 241–242 (2009).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing